http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2017209106-A1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
filingDate 2017-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2018-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-WO2017209106-A1
titleOfInvention Tipepidine oral formulation
abstract The present invention relates to a new once or twice daily oral dose containing tipepidine or a pharmaceutically acceptable salt thereof by controlling the drug dissolution rate of tipepidine or a pharmaceutically acceptable salt thereof. A composition is provided.
priorityDate 2016-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425978919
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454301003
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426383081
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494062
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID203585
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3318739
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID131752735
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22475
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448897384
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5484
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448487131
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24441
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6321303
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453728540

Total number of triples: 54.